Fate Therapeutics, Inc.
General ticker "FATE" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $150.9M (TTM average)
Fate Therapeutics, Inc. follows the US Stock Market performance with the rate: 52.0%.
Estimated limits based on current volatility of 4.2%: low 2.70$, high 2.93$
Factors to consider:
- Total employees count: 161 (-11.0%) as of 2025
- Top business risk factors: Regulatory and compliance, Manufacturing risks, Clinical trial delays, Inability to raise capital, Labor/talent shortage/retention
- Current price 38.3% above estimated high
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.65$, 2.01$]
- 2026-12-31 to 2027-12-31 estimated range: [0.75$, 2.19$]
Financial Metrics affecting the FATE estimates:
- Positive: with PPE of -0.9 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of 92.20 > -0.60
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Inventory ratio change, % of -2.62 <= -0.75
- Positive: Shareholder equity ratio, % of 64.96 > 64.23
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term FATE quotes
Long-term FATE plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $63.53MM | $13.63MM | $6.65MM |
| Operating Expenses | $254.04MM | $223.91MM | $154.35MM |
| Operating Income | $-190.51MM | $-210.28MM | $-147.70MM |
| Non-Operating Income | $29.58MM | $24.01MM | $11.39MM |
| R&D Expense | $172.60MM | $135.00MM | $107.83MM |
| Income(Loss) | $-160.93MM | $-186.26MM | $-136.31MM |
| Net Income(Loss)* | $-160.93MM | $-186.26MM | $-136.31MM |
| Stockholders Equity | $368.42MM | $318.73MM | $207.18MM |
| Assets | $506.22MM | $440.69MM | $318.94MM |
| Operating Cash Flow | $-132.26MM | $-122.87MM | $-106.08MM |
| Capital expenditure | $6.15MM | $0.73MM | $5.95MM |
| Investing Cash Flow | $112.67MM | $12.22MM | $111.17MM |
| Financing Cash Flow | $0.09MM | $99.89MM | $5.49MM |
| Earnings Per Share** | $-1.64 | $-1.64 | $-1.15 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.